Food and drug administration Announces Advisory Committee Meeting on Sandoz’s Etanercept Biosimilar

, Concepts

Food and drug administration Announces Advisory Committee Meeting on Sandoz’s Etanercept Biosimilar

We formerly reported on Sandoz’s aBLA for any biosimilar of Amgen’s ENBREL (etanercept) and also the related BPCIA litigation.

The FDA’s Joint disease Advisory Committee announced today that it’ll hold an open advisory committee meeting on This summer 13, 2016 to go over Sandoz’s etanercept biosimilar. Based on the announcement, anybody wishing to create a formal dental presentation must inform the committee hr person by June 20, 2016, and then any written submissions should be produced by June 28, 2016.

 

Leave a Reply